×
About 17,298 results

ALLMedicine™ Hematopoietic Stem Cell Transplantation Center

Research & Reviews  6,304 results

Novel therapeutics and targets in myelofibrosis.
https://doi.org/10.1080/10428194.2021.2010068
Leukemia & Lymphoma; Waksal JA, Harrison CN et. al.

Dec 3rd, 2021 - Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and sy...

First report of successful treatment for hemoglobin Bristol-Alesha by hemopoietic stem ...
https://doi.org/10.1007/s00277-021-04721-7 10.1016/j.medcli.2018.05.013 10.1007/978-1-4939-7299-9_4 10.1097/01.mph.0000175409.21342.ea 10.1080/03630260701459408 10.1016/j.mcna.2016.09.008 10.1182/blood.V88.1.341.341 10.1101/cshperspect.a011858
Annals of Hematology; Li S, Chen K et. al.

Dec 2nd, 2021 - HBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds of hemolytic anemia, such as hemoglobin Bristol-Alesha, are rarely reported, no ideal treatment ...

Outcome of Viral-associated Hemophagocytic Lymphohistiocytosis at a Tertiary Hospital.
https://doi.org/10.1097/INF.0000000000003401
The Pediatric Infectious Disease Journal; Nazir HF, Hassanein N et. al.

Dec 1st, 2021 - Little is known about viral-associated hemophagocytic lymphohistiocytosis (HLH) in Oman. This study was done to assess the epidemiology, clinical features and outcome of viral-associated HLH in our setting. We retrospectively reviewed children (0-...

Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocyto...
https://doi.org/10.1080/17474086.2021.2009337
Expert Review of Hematology; Yao Y, Tang Y et. al.

Dec 1st, 2021 - Thrombocytopenia is a tough complication after hematopoietic stem cell transplantation (HSCT) with elusive pathogenesis and lack of well-established therapies. Thrombopoietin receptor agonists (TPO-RAs) have been used for thrombocytopenia post HSC...

see more →

Guidelines  15 results

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell trans...
https://doi.org/10.1182/bloodadvances.2021004394C
Blood Advances; Kanter J, Liem RI et. al.

Sep 29th, 2021 - Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for SCD; howe...

Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Asses...
https://doi.org/10.1097/TP.0000000000003569
Transplantation Bonifazi F, Sica S et. al.

Dec 5th, 2020 - Variation in clinical practice affects veno-occlusive disease management, mainly in patients who undergo allogeneic hematopoietic stem cell transplantation. Disputes about diagnostic criteria, treatment, and prophylaxis, due to the lack of high-qu...

Sinusoidal obstruction syndrome.
https://doi.org/10.1016/j.clinre.2020.03.019
Clinics and Research in Hepatology and Gastroenterology; de Lédinghen V, Villate A et. al.

Apr 8th, 2020 - Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease, is characterized by concentric and non-thrombotic obstruction of the sinusoid and central vein lumen with no identified primitive or thrombotic hepatic vein lesions...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Recommendations on hematopoietic stem cell transplantation for inherited bone marrow fa...
https://doi.org/10.1038/bmt.2015.117
Bone Marrow Transplantation; Peffault de Latour R, Peters C et. al.

Jun 9th, 2015 - Allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential to cure patients with an inherited bone marrow failure syndrome (IBMFS). However, the procedure involves the risk of treatment-related mortality and may be associated w...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  338 results

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
https://clinicaltrials.gov/ct2/show/NCT01890486

Nov 25th, 2021 - To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is...

Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever
https://clinicaltrials.gov/ct2/show/NCT04270786

Nov 25th, 2021 - This is a randomized study to evaluate the safety and feasibility of early de-escalation treatment of empyrical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplantation (HSCT). All patients undergoing ...

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
https://clinicaltrials.gov/ct2/show/NCT01176006

Nov 24th, 2021 - Background Mutations in the Dedicator of Cytokinesis-8 (DOCK8) gene are responsible for an immunodeficiency disease characterized by: severe cutaneous and sinopulmonary infections with bacterial organisms; extensive cutaneous viral infections with...

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT04762875

Nov 24th, 2021 - This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative hematopoietic stem cell transplantation (HSCT) in recipients with hemato...

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
https://clinicaltrials.gov/ct2/show/NCT04056611

Nov 24th, 2021 - RSV is recognized as major respiratory pathogen in infants and young children and causes upper and lower respiratory illness among all age groups, often going undiagnosed. Immunocompromised (IC) participants have a reduced ability to combat infect...

see more →

News  250 results

Clinical Edge Journal Scan Commentary: CML November 2021
https://www.mdedge.com/hematology-oncology/article/248161/cml/clinical-edge-journal-scan-commentary-cml-november-2021
Javier Pinilla-Ibarz MD, PhD

Nov 2nd, 2021 - Javier Pinilla-Ibarz MD, PhD In the new era of the COVID-19 pandemic, patients and physicians still struggle to see how different hematologic conditions may be affected by this viral infection. Although it has been well reported that COVID-19 may.

Allo-HSCT in CR1 beneficial for elderly AML patients with unfavorable or intermediate-risk cytogenetics
https://www.mdedge.com/hematology-oncology/article/247824/aml/allo-hsct-cr1-beneficial-elderly-aml-patients-unfavorable-or

Oct 24th, 2021 - Key clinical point: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first complete remission (CR1) after intensive chemotherapy (IC) offered clinical benefits in elderly patients with intermediate- or unfavorable-risk acute m.

Immunotherapy Demonstrates Early Promise Across Lymphoma Subgroups
https://www.onclive.com/view/immunotherapy-demonstrates-early-promise-across-lymphoma-subgroups

Oct 6th, 2021 - Stephen M. Ansell, MD, PhD Checkpoint inhibitors are making their way through the treatment paradigm of lymphomas with 2 FDA approvals in the last year. Now, combinations are likely next, as early results demonstrate encouraging activity across v...

Enasidenib vs. standard of care therapies prolongs survival in patients with R/R AML with IDH2 mutation
https://www.mdedge.com/hematology-oncology/article/246631/aml/enasidenib-vs-standard-care-therapies-prolongs-survival

Sep 26th, 2021 - Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 ( IDH2) mutat.

Off-the-Shelf NK Cell Products FT596 and FT516 Show Early Promise in B-cell Lymphoma
https://www.onclive.com/view/off-the-shelf-nk-cell-products-ft596-and-ft516-show-early-promise-in-b-cell-lymphoma

Sep 2nd, 2021 - Regimens that included the off-the-shelf, induced pluripotent stem cell (iPSC)–derived natural killer (NK) cell products FT596 and FT516 were found to elicit encouraging responses with favorable tolerability when used in patients with B-cell lymph...

see more →